Christopher J. Weber

798 total citations · 1 hit paper
32 papers, 278 citations indexed

About

Christopher J. Weber is a scholar working on Psychiatry and Mental health, Physiology and Economics and Econometrics. According to data from OpenAlex, Christopher J. Weber has authored 32 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 14 papers in Physiology and 13 papers in Economics and Econometrics. Recurrent topics in Christopher J. Weber's work include Dementia and Cognitive Impairment Research (20 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Alzheimer's disease research and treatments (12 papers). Christopher J. Weber is often cited by papers focused on Dementia and Cognitive Impairment Research (20 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Alzheimer's disease research and treatments (12 papers). Christopher J. Weber collaborates with scholars based in United States, Switzerland and Denmark. Christopher J. Weber's co-authors include María C. Carrillo, Dorene M. Rentz, Eric Siemers, Ronald C. Petersen, Alireza Atri, J. Scott Andrews, Paul Aisen, Brandy R. Matthews, Lisa J. Bain and Gil D. Rabinovici and has published in prestigious journals such as Journal of Nuclear Medicine, JAMA Neurology and Alzheimer s & Dementia.

In The Last Decade

Christopher J. Weber

30 papers receiving 267 citations

Hit Papers

Updated appropriate use criteria for amyloid and tau PET:... 2025 2026 2025 5 10 15 20 25
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
    2025 29 citations Gil D. Rabinovici, David S. Knopman et al. Alzheimer s & Dementia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher J. Weber United States 10 126 114 64 54 29 32 278
Nada Abdalla United States 5 171 1.4× 224 2.0× 54 0.8× 44 0.8× 34 1.2× 7 446
Miia Kivipelto Sweden 11 177 1.4× 163 1.4× 38 0.6× 22 0.4× 45 1.6× 37 440
Sheila Seleri Assunção United States 9 99 0.8× 175 1.5× 34 0.5× 57 1.1× 24 0.8× 14 318
Carolyn Langlois United States 5 94 0.7× 90 0.8× 45 0.7× 33 0.6× 35 1.2× 14 199
Cynthia Olson United States 4 196 1.6× 264 2.3× 72 1.1× 23 0.4× 34 1.2× 8 390
Juraj Sečník Sweden 12 66 0.5× 157 1.4× 22 0.3× 24 0.4× 15 0.5× 18 330
Kasia Lobello United States 8 112 0.9× 116 1.0× 20 0.3× 146 2.7× 9 0.3× 10 434
Ara Khachaturian United States 4 181 1.4× 221 1.9× 14 0.2× 23 0.4× 23 0.8× 10 396
Rebecca Bothwell United States 9 113 0.9× 103 0.9× 24 0.4× 21 0.4× 21 0.7× 17 279
A Miners Canada 7 69 0.5× 83 0.7× 51 0.8× 102 1.9× 24 0.8× 10 315

Countries citing papers authored by Christopher J. Weber

Since Specialization
Citations

This map shows the geographic impact of Christopher J. Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher J. Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher J. Weber more than expected).

Fields of papers citing papers by Christopher J. Weber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher J. Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher J. Weber. The network helps show where Christopher J. Weber may publish in the future.

Co-authorship network of co-authors of Christopher J. Weber

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher J. Weber. A scholar is included among the top collaborators of Christopher J. Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher J. Weber. Christopher J. Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rabinovici, Gil D., David S. Knopman, Javier Arbizu, et al.. (2025). Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimer s & Dementia. 21(1). e14338–e14338. 29 indexed citations breakdown →
2.
Rabinovici, Gil D., David S. Knopman, Javier Arbizu, et al.. (2025). Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Journal of Nuclear Medicine. 66(Supplement 2). S5–S31. 10 indexed citations
3.
Petersen, Ronald C., Ana Graf, Susan De Santi, et al.. (2025). Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(1). e70038–e70038. 1 indexed citations
4.
Windon, Charles, Constantine Gatsonis, María C. Carrillo, et al.. (2025). Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study. Alzheimer s & Dementia. 21(7). e70504–e70504. 1 indexed citations
5.
Weninger, Stacie, Michael C. Irizarry, Adam Fleisher, et al.. (2024). Alzheimer's disease drug development in an evolving therapeutic landscape. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(4). e70015–e70015. 1 indexed citations
6.
Eldik, Linda J. Van, Eric Siemers, Emily C. Collins, et al.. (2024). Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(4). e70014–e70014. 1 indexed citations
7.
Jack, Clifford R., Ana Graf, Samantha C. Burnham, et al.. (2024). Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(4). e70013–e70013. 3 indexed citations
8.
Rentz, Dorene M., Paul Aisen, Alireza Atri, et al.. (2024). Benefits and risks of FDA‐approved amyloid‐targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician‐patient engagement. Alzheimer s & Dementia. 20(11). 8162–8171. 7 indexed citations
9.
Welsh‐Bohmer, Kathleen A., Geoffrey A. Kerchner, Shobha Dhadda, et al.. (2023). Decision making in clinical trials: Interim analyses, innovative design, and biomarkers. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(4). e12421–e12421. 1 indexed citations
10.
Petersen, Ronald C., Ana Graf, Susan De Santi, et al.. (2023). Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(4). e12434–e12434. 3 indexed citations
11.
Rabinovici, Gil D., María C. Carrillo, Charles Apgar, et al.. (2023). Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA Neurology. 80(11). 1166–1166. 7 indexed citations
12.
Albala, Bruce, Susan De Santi, Gregory Klein, et al.. (2023). The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB). Alzheimer s & Dementia. 20(1). 695–708. 4 indexed citations
13.
Petersen, Ronald C., Paul Aisen, J. Scott Andrews, et al.. (2023). Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer s & Dementia. 19(6). 2730–2736. 60 indexed citations
14.
Rabinovici, Gil D., David S. Knopman, Javier Arbizu, et al.. (2023). Updated Appropriate Use Criteria for Amyloid and Tau PET. Alzheimer s & Dementia. 19(S14). 9 indexed citations
15.
Rentz, Dorene M., Alette M. Wessels, Ananth Annapragada, et al.. (2021). Building clinically relevant outcomes across the Alzheimer's disease spectrum. Alzheimer s & Dementia Translational Research & Clinical Interventions. 7(1). e12181–e12181. 28 indexed citations
16.
Jicha, Gregory A., Erin L. Abner, Steven E. Arnold, et al.. (2021). Committee on High‐quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimer s & Dementia. 18(6). 1109–1118. 9 indexed citations
17.
Peters, Ruth, John C.S. Breitner, Sarah‐Naomi James, et al.. (2021). Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in‐depth exploration of seven established risk factors. Alzheimer s & Dementia Translational Research & Clinical Interventions. 7(1). e12202–e12202. 3 indexed citations
18.
Salloway, Stephen, Kumar Budur, Ronald B. DeMattos, et al.. (2020). Advancing combination therapy for Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 6(1). e12073–e12073. 42 indexed citations
19.
McDade, Eric, Martin M. Bednar, H. Robert Brashear, et al.. (2020). The pathway to secondary prevention of Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 6(1). e12069–e12069. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nada Abdalla Breakdown of academic impact, for papers by Miia Kivipelto Breakdown of academic impact, for papers by Sheila Seleri Assunção Breakdown of academic impact, for papers by Carolyn Langlois Breakdown of academic impact, for papers by Cynthia Olson Breakdown of academic impact, for papers by Juraj Sečník Breakdown of academic impact, for papers by Kasia Lobello Breakdown of academic impact, for papers by Ara Khachaturian Breakdown of academic impact, for papers by Rebecca Bothwell Breakdown of academic impact, for papers by A Miners
Rankless by CCL
2026